Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POD1UM-204 umbrella study of retifanlimab-based therapy in advanced or metastatic endometrial cancer
2022-502600-79-00Phase 2Completed
- Sponsor
- Incyte
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of retifanlimab in endometrial cancer (EC) (6 arms), sponsored by Incyte. Primary endpoint: Objective response rate. Started Nov 2023; status: completed.
02
Drugs
retifanlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2022-502600-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502600-79-00.